Yahoo Web Search

  1. This new type structure has only been witnessed in the lab, and its existence in living human cells had been deemed impossible. A ground-breaking discovery reveals that there’s more to our DNA ...

  2. Email This Story Send this story to: ** Enter the e-mail address of the recipient. Separate multiple addresses with commas. Add your own personal message. Enter your e-mail address: ** ** denotes ...

  3. The "Asia-Pacific Anti-Nuclear Antibody Test Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2025" report has been added to ResearchAndMarkets.com's offering ...

  4. As a result, Prothena is discontinuing development of the antibody-based medicine for the condition. The news is a win for short sellers who have targeted the stock but a fresh setback ...

  5. In a new DNA twist, Australian scientists have found another structure in living human cells besides the familiar double helix. Called the “i-motif,” it’s a four-stranded knot of DNA thought ...

  6. (nyse/tsx:ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that Celgene Corporation has exercised its right to expand its collaboration ...

  7. The decision was based on results from the Phase 2b PRONTO study and a futility analysis of the Phase 3 VITAL study. Based on the results from the Phase...

  8. ...biological cancer therapy, has been designed to induce cell death against cancer or infected cells by three different modes of action: (1) Direct killing using activated NK cells (aNK) that release toxic granules directly into the cell through cell to cell contact, (2) Antibody-mediated killing using haNKs, which are NK cells engineered to incorporate a high affinity receptor that binds to an...

  9. The phase 3 trial, called ARTIC, examines the efficacy of Imfinzi and tremelimumab--two antibody therapies--in treating certain NSCLC variants.

  10. Under the terms of the agreement, Zhejiang Teruisi Biopharmaceutical, Inc. will gain access to EpimAb’s Fabs-In-Tandem Immunoglobulin...

  1. 12345264 results